Lucius Pharmaceuticals Laos

Today's factory visit
Laos Lucius Pharmaceutical Canteen
Let's see what they had for lunch today

Lucius Pharmaceutical Factory (Laos), Canteen, Today’s Menu

Lucius Pharmaceutical Factory · The Most Beautiful Sunset

Zongertinib (Hernexeos): New Hope for HER2-Mutant NSCLC
Zongertinib (brand: Hernexeos) is a breakthrough oral targeted therapy for HER2 mutation-positive non-small cell lung cancer (NSCLC).
✅ Highly selective: blocks mutant HER2, spares healthy EGFR (fewer side effects like rash/diarrhea)
✅ Oral once-daily: easy to take, no IV infusion✅ Strong efficacy: ORR ~71–77%, median PFS ~12.4 months
✅ Brain activity: effective even in patients with brain metastases
For adults with unresectable/metastatic HER2-mutant NSCLC (pretreated or first-line).

Lucius pharmaceuticals factory in Laos

Welcome to Lucius Pharmaceutical Factory. We specialize in a variety of anti-tumor targeted drugs, chemotherapeutic drugs and immunotherapeutic drugs, protecting health with professionalism.

a third-generation EGFR tyrosine kinase inhibitor for EGFR-mutated non-small cell lung cancer (NSCLC). It is indicated for first-line treatment, adjuvant therapy after surgery, and for patients with T790M mutation. It crosses the blood-brain barrier and provides consistent clinical benefit across stages.
Disclaimer: For educational purposes only. Not medical advice.

Lucius Pharmaceuticals Laos Publicity introduction